Genetic epidemiological pipeline identifies candidate markers of clozapine-induced metabolic dysfunction: implications for precision prescribing.
Genetic markers may predict which treatment-resistant patients will develop metabolic side effects from a powerful psychiatric medication, enabling safer prescribing.
Genetic epidemiological pipeline identifies candidate genomic markers for clozapine-induced metabolic dysfunction, enabling precision prescribing strategies to reduce cardiometabolic toxicity in treatment-resistant schizophrenia. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- genomic_association_study
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- The World Journal of Biological Psychiatry
Why it surfaced
Pharmacogenomic markers for clozapine metabolic toxicity; precision prescribing application in treatment-resistant schizophrenia with cardiometabolic comorbidity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.